CJC-1295 (With DAC) | Pen

CJC-1295 (With DAC) is a peptide positioned for controlled research settings where growth hormone (GH) / IGF-1 axis regulation is being studied in relation to GH pulsatility and secretion dynamics, IGF-1 exposure profiles, and body-composition and metabolic endpoints.

Supports

1. Prolonged GH/IGF-1 exposure profiling in human pharmacology models
2. GHRH receptor–mediated pituitary signaling readouts in experimental systems
3. GH pulsatility characterization under long-acting GHRH analog stimulation
4. Body-composition outcome frameworks (lean mass/fat mass) in study design contexts
5. Metabolic endpoint monitoring (insulin sensitivity/glucose handling) in controlled models

Description

CJC-1295 with DAC is a long-acting growth hormone–releasing hormone (GHRH) analog engineered to extend systemic exposure by covalently associating with endogenous serum albumin. This “drug affinity complex” (DAC) concept is used to reduce rapid clearance and enable multi-day pharmacokinetics, supporting chronic-exposure study designs with fewer administrations compared with short-acting GHRH fragments.

In controlled research settings, CJC-1295 (DAC) is primarily used to investigate GH/IGF-1 axis regulation, including the magnitude and duration of GH release, downstream IGF-1 elevation, and how sustained exposure interacts with endogenous pulsatile secretion patterns. Human data in healthy adults report dose-dependent increases in circulating GH and IGF-1 that persist for days to weeks depending on dosing schedule and sampling design.

Because GH and IGF-1 influence multiple physiological domains (growth signaling, substrate metabolism, tissue remodeling), experimental programs often pair endocrine readouts (GH pulse analysis, IGF-1 time course) with functional endpoints such as body composition, strength proxies, and metabolic markers. Observations are model- and protocol-dependent and should be interpreted within the limitations of each study design.

Clinical Status

CJC-1295 (DAC) has published human clinical pharmacology data demonstrating sustained, dose-dependent increases in circulating GH and IGF-1 in healthy adults, along with detailed pharmacokinetic estimates consistent with prolonged half-life. Additional preclinical work supports the albumin-bioconjugation concept and pituitary receptor activation in animal models. These data position CJC-1295 (DAC) primarily as a research tool for GH/IGF-1 axis studies rather than an established, regulator-approved therapy.

Evidence type:
Human RCT ✔ | Observational ☐ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

CJC-1295 is designed as a GHRH receptor agonist analog, promoting pituitary GH release via upstream signaling rather than providing exogenous GH. The DAC modification enables covalent association with serum albumin, extending systemic residence time and maintaining receptor-accessible exposure over multiple days, which is reflected in prolonged GH and IGF-1 responses in human studies.

Mechanistically, study designs often evaluate (1) endocrine dynamics (GH pulse frequency/amplitude, integrated GH exposure), (2) downstream hepatic IGF-1 production and persistence, and (3) secondary systems potentially influenced by sustained GH/IGF-1 signaling (substrate metabolism, body-composition trajectories, and tissue remodeling markers). Outcomes can vary with baseline physiology, sampling methodology, and dose/timing protocols.

Benefits

• Long-acting endocrine exposure model:
  Enables multi-day GH/IGF-1 stimulation profiles suitable for chronic-exposure experimental designs.
• GHRH-receptor pathway interrogation:
  Supports mechanistic studies focused on pituitary GHRH receptor activation and downstream signaling.
• GH pulsatility analysis frameworks:
  Used in protocols assessing whether pulsatile GH secretion patterns persist under prolonged GHRH-analog exposure.
• Body-composition endpoint integration:
  Commonly included in research programs examining lean mass/fat mass dynamics alongside endocrine markers.
• Metabolic outcome monitoring:
  Provides a platform to study insulin sensitivity and glucose-handling endpoints in relation to sustained IGF-1 exposure.
• Albumin-bioconjugation pharmacokinetics:
  Acts as a reference compound for evaluating albumin-binding strategies that extend peptide half-life and reduce clearance.

Research Data

Stack Suggestions

In extended experimental designs, CJC-1295 (With DAC) is sometimes paired with:

• Ipamorelin → to explore combined GHRH + GHSR pathway stimulation in endocrine-response studies
• GHRP-2 (or related GHSR agonists) → to compare pulse architecture vs. sustained exposure designs in GH output experiments
• Tesamorelin → as a comparator GHRH analog in study designs focused on IGF-1 kinetics and metabolic endpoints

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Possible Side Effects

Possible effects reported or discussed in research and clinical pharmacology contexts can include injection-site reactions, transient headache or flushing, fluid-retention–type symptoms, and laboratory shifts consistent with GH/IGF-1 axis activation (e.g., changes in IGF-1 levels and glucose/insulin-related markers). Because the DAC design prolongs exposure, any endocrine-related effects may persist longer than with short-acting analogs. Immunogenicity (e.g., antibody formation) and individual variability are additional considerations in controlled studies; outcomes are model- and protocol-dependent.

Scientific References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — Human RCT
• Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog — Human (physiology study)
• Human growth hormone-releasing factor (hGRF)1–29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Animal
• Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes GH pulsatility and increases IGF-I levels in older adults — Human (clinical physiology)
• Activation of the GH/IGF-1 axis by CJC-1295, a long acting analog of GHRH — Review (Human/Animal)
• Advances in the detection of growth hormone releasing hormone (GHRH) analogs: in vitro metabolism and analytical detection including CJC-1295 and CJC-1295 with DAC — In vitro
• Qualitative identification of growth hormone-releasing peptides and analogs in unknown pharmaceutical preparations — Analytical (In vitro)
• EU Clinical Trials Register: Phase 2 study of CJC-1295 administered for 12 weeks in HIV-infected patients with HIV-associated visceral obesity — Human (trial registry)
• FDA briefing document attachment discussing CJC-1295 (DAC) half-life and clinical development context — Regulatory context
• FDA document attachment summarizing CJC-1295 (DAC) development notes and trial context — Regulatory context

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.